Objectives To summarise the epidemiological evidence on the relationship between second-(OC2) and thirdgeneration (OC3) oral contraceptives (OC) and the mortality associated with deep vein thrombosis (DVT) and myocardial infarction (MI), and to extrapolate and balance the evidence for these risks to the population of French OC users.
Introduction
Physicians want their decision to prescribe an oral contraceptive (OC) to result in an effective prevention of pregnancy; that is, for the OC to do what it is intended to do with a limited amount of harm. However, balancing benefit with risk can be a challenging endeavour in the face of conflicting or diffuse evidence of harm. This is particularly true for the choice of prescribing either a second-or third-generation OC (OC2 or OC3).
There is a dearth of comparative evidence to help physicians balance the risks of death from deep vein thrombosis (DVT) and myocardial infarction (MI) with the benefits of oral contraception, especially on a population basis. However, there is now some evidence that tries to quantify these two effects, albeit separately. For example, based on a review of the main studies published at this time [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] (and an unpublished Wyeth-Ayerst Research Report, 1997), the Committee for Proprietary Medicinal Products (CPMP) expert report stated that, compared to OC2, OC3 were associated with an increased risk of DVT, the OC3/OC2 relative risk being said to be in the range of 1.5 to 2. 20 This is in agreement with the meta-analysis published the same year by Hennessy et al. 21 that concluded in a relative risk of 1.7 [95% confidence interval (CI) 1.3-2.1]. Conversely, the case-control study published in 2002 by Lidegaard et al. 22 found an odds ratio (OR) of 1.3 (95% CI 1.0-1.8).
The relative impact of OC2 and OC3 on the mortality associated with MI is also not clear. For Dunn et al., 23 OC3 users could have a higher risk of MI (OR OC3/OC2 = 1.8, 95% CI 0.66-4.83) while no difference was shown by the World Health Organization study 24 (OR OC3/nonOC = 1.0, 95%CI 0.1-7.0 and OR OC2/nonOC = 1.6, 95% CI 0.5-5.5). In contrast, Lewis et al. 25 (OR OC3/OC2 = 0.28, 95% CI 0.09-0.86), Tanis et al. 26 (OR OC3/OC2 = 0.52, 95% CI 0.23-1.18) and Lidegaard and Estrom 27 (OR OC3/OC2 = 0.51, 95% CI 0.15-1.72) found a reduction in risk in OC3 users.
In the present study, we used the epidemiological evidence to summarise the potential impact of OC choice on women's DVT and MI mortality in the actual population of OC users of a European country, namely France.
Methods

DVT computing
The studied population were women aged between 20 and 44 years. For both the OC3/OC2 relative risk of DVT and the baseline incidence of DVT in these age groups we used two sources: (1) the CPMP public assessment report published by the European Medicines Evaluation Agency in 2001 20 which reviewed the studies published on the subject until 2001 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] (and an unpublished Wyeth-Ayerst Research Report, 1997) and (2) the results of two studies published later on the same topic, namely a meta-analysis 21 and a case-control study 22 retrieved after a MEDLINE literature search 28 using the MeSH terms 'oral contraceptive' and 'deep venous thrombosis'. In a sensitivity analysis we considered the two extreme estimates of the relative risk mentioned in these sources, i.e. 1.3 and 2.
The baseline incidence of DVT in women not using OCs and aged 15-44 years is 5-10 per 100 000 woman-
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years. 20, 29 The incidence of DVT in women using OC2 was estimated to be about 20 per 100 000 woman-years. 20 It is currently stated 20, 29 that about 10% of DVT lead to pulmonary embolism and 1-2% to death.
The number of excess fatal DVT associated with OC3 use was obtained by multiplying the overall risk of DVT in OC2 by the relative risk, OC3/OC2 (i.e. 1.3 or 2, according to the sources previously mentioned. The two values of the absolute risk (OC2 and OC3) were applied to the actual population of French OC users. Data on the number of users in France and in each age group were obtained from the COCON study. 30 
MI computing
First, we conducted a MEDLINE literature search 28 using the MeSH terms 'oral contraceptive' and 'myocardial infarction', or 'cardiovascular disease'. This search was restricted to studies classified as case-control or cohort studies. We identified five studies that attempted to assess the risk of MI associated with the use of OC2 and OC3. [23] [24] [25] [26] [27] We applied the values of the OR published in these studies to the actual population of French OC users (categorised into 5-year age groups). First, the numbers of MI deaths for this population were extracted from the gender-and age-specific mortality rates for the French general population published yearly by the Institut National de la Santé et de la Recherche Médicale. 31 As regards DVT, data on the number of OC users in France and in each age group were obtained from the COCON study. 30 The proportion of fatal MIs that would be avoided or induced by the systematic use of OC3 by all OC users in each age group was obtained through the classical formula for the aetiological fraction of the risk in a population (EFR pop ):
where E pop is the proportion of OC users among women of a given age group and OR is the estimate of the odds ratio obtained in each study. These ratios, which vary from 0.28 27 to 1.8 25 , estimate the relative risk in OC3 users vs OC2 users. As the studies did not give a specific OR value for fatal MIs, we assumed that the relative risks found in the studies apply both to non-fatal and fatal MIs. In other words, no study has to date shown a difference in mortality between MI cases induced by OCs and by other causes.
The number of fatal MIs associated with OC use was obtained simply by multiplying in each age group the total number of MI deaths by the corresponding EFR pop .
Results
As mentioned above, the OC3/OC2 relative risk of DVT was between 1.5 and 2 for the CPMP expert group, 20 
Discussion
The comparative cardiovascular risks of OC2 and OC3 have been debated for a number of years; the publication of the first studies having resulted in the infamous 'pill scare' in Europe, mainly in the UK. 32 From public health and clinical practice points of view, the key issue is to assess the impact in real-life conditions of differences between OC2 and OC3 suggested by published studies.
The main contribution of the present study to this debate is the quantification, through deaths, of these differences by applying estimates of relative risks found in the above five studies to an actual population of OC users in a developed country.
The results were derived from observed clinical practice in one of these countries, namely France, and took into account the number of users and the data on mortality from MI, both adjusted for age groups. The presented model allows one to produce an estimate of the relative impact of a given strategy, even if an ad hoc study is not available for the considered country.
On account of the wide variability in the OR estimates found in the various studies published to date, and the differences in the study designs that were used, we ruled out the possibility of conducting a meta-analysis. We preferred to enter each study result separately in the modelling process. On account of the very low incidence of cardiovascular mortality in the age groups for which the prevalence of OC use is the highest, the population impact of the choice between OC2 and OC3 appears to be relatively small. It could be argued that one of the parameters used for the computation of the number of MI deaths was the OC3/OC2 relative risks found in the five studies conducted in other European countries. The main and obvious reason was that no such study was available for France. Furthermore, even if one could argue that these risks could be in part country dependent, such an extrapolation of evidence is currently accepted for those regulatory decisions concerning both approval and drug safety. Moreover, our conclusions would not be altered dramatically even when considering a higher baseline risk of MI in some European countries because of its low incidence in these age groups of women.
When considering the size and the type of population concerned, i.e. healthy women, the question of the relative benefit/risk ratio between OC2 and OC3 is crucial both for prescription and regulatory decisions. The concerns about the impact of OC2 and OC3 on DVT and MI risks have induced intense controversies and marketing pressures. 32 The relevant answer should be expressed in terms of actual impacts and not of relative risks of statistical significance.
The low magnitude of the differences found in the present study are in agreement with figures derived from the meta-analysis by Spitzer et al. 33 in which it was found that the risk of MI was about two times lower (OR = 0.44) for OC3 compared to OC2. Applying this estimate to the population considered in the present study generates a figure of 18 prevented deaths, i.e. 1.74 per million inhabitants and per year.
Even if the present analysis did not consider other types of adverse reactions and risks possibly associated with OC use (e.g. breast cancer and liver tumours), it is difficult to conclude that the global cardiovascular risk is significantly lower for either of the two OC strategies.
